Showing results (21-30 of 223) with videos related to

Sort By:
Pageof 23
Bulletin Du Cancer|May 16, 2018
[WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic methods]Victor Sarradin, Aurore Siegfried, Emmanuelle Uro-Coste, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumorsLuis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Expert Opinion on Investigational Drugs|September 28, 2005
Vinflunine: a novel antitubulin agent in solid malignanciesJaafar Bennouna, Mario Campone, Jean Pierre Delord, et al.
Cureus|December 2, 2024
Regorafenib-Triggered Hemophagocytic Lymphohistiocytosis: A Report of Two CasesIlfad Blazevic, Nadim Fares, Blandine Delaunay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckChristophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Bulletin Du Cancer|June 3, 2004
[Demography of oncologic practitioners working in France. Projection elements for the next 30 years]P Rivera, Jean-Pierre Delord, P Grosclaude, et al.
Springerplus|January 4, 2014
Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatmentSabrina Boyrie, Isabelle Fauquet, Michel Rives, et al.
Cancers|August 12, 2022
Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis BlockadeCarlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, et al.
Clinical and Translational Science|March 20, 2021
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancerCarlos Gomez-Roca, Caroline Even, Christophe Le Tourneau, et al.
Clinical Lung Cancer|December 10, 2017
Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I StudyCarole Massabeau, Jonathan Khalifa, Thomas Filleron, et al.
Pageof 23